#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ductal adenocarcinoma of pancreas Cardiac amyloidosis Acute graft versus host disease in liver Cutaneous T-cell lymphoma stage I Cataract Factor IX deficiency Malignant peritoneal neoplasm Renal cell carcinoma Arteriosclerosis Acute lymphocytic leukaemia recurrent Stress cardiomyopathy Chronic kidney disease Mucopolysaccharidosis I Central nervous system lymphoma Neurodegenerative disorder More trials…

    Learn about Rare Diseases

    Hereditary ataxia – Life with Disease Lennox-Gastaut syndrome – Diagnostics Breast angiosarcoma – Diagnostics Hairy cell leukaemia recurrent – Trials in Disease Lymphangioma Osteosarcoma metastatic – Trials in Disease Myelodysplastic syndrome with excess blasts Lymphangioma – Basic Information Synovial sarcoma – Treatment Ewing’s sarcoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Migalastat Tivozanib Clemizole Hydrochloride Fingolimod O15-Water Vo659 LUNSEKIMIG FLUORIDE VINBLASTINE Abt-494 Nido-361 Satralizumab M1P Dipotassium Salt ATOVAQUONE Ifezuntirgene Inilparvovec Relebactam [18F]-Altanserin Amantadine Hydrochloride Leriglitazone GSKVX000000044501 More therapies…

    Learn about Your Condition

    Vulvovaginal discomfort Lymphatic malformation Thymic carcinoma Chondrosarcoma metastatic Malignant melanoma of eyelid Corneal graft failure Cancer pain Cardiac failure Sarcoma Precocious puberty Merycism Ventricular tachycardia HER2 positive breast cancer Bacterial prostatitis Addison's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Multifocal motor neuropathy

  • Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Multifocal motor neuropathy
    Investigated Drugs:
    • Human Normal Immunoglobulin (Iv)
    • Empasiprubart
    Austria Belgium Czechia Denmark Estonia France +13

  • Study on the Safety and Effects of DNTH103 for Adults with Multifocal Motor Neuropathy

    Not recruiting

    2 1
    Investigated Diseases:
    • Multifocal motor neuropathy
    Investigated Drugs:
    • Dnth103
    Denmark France Italy The Netherlands Poland Spain

  • Study on Long-term Safety and Effects of ARGX-117 for Adults with Multifocal Motor Neuropathy

    Not recruiting

    2 1
    Investigated Diseases:
    • Multifocal motor neuropathy
    Investigated Drugs:
    • Empasiprubart
    Austria Belgium France Germany Italy The Netherlands +2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!